MiNK director receives stock grants as board pay

MiNK Therapeutics director Barbara Ryan reported stock-based board compensation rather than open-market trades.

Rhea-AI Filing Summary

MiNK Therapeutics director Barbara Ryan reported stock-based board compensation rather than open-market trades. On June 1, 2026, she received 1,434 shares of common stock valued at $12.38 per share as a grant in lieu of cash retainers, bringing her direct holdings to 23,469 shares.

The filing also reports a prior grant on March 2, 2026 of 1,629 shares at $10.90 per share, likewise received instead of cash board and committee fees. Footnotes explain these awards are restricted stock units that convert into one share each and vest one month after grant, and that the Q1 2026 RSUs were filed late due to an administrative error.

Insider Trade Summary

Grant/Award: 3,063 shares

Grant/Award 2 txns

Insider Ryan Barbara

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,434	$12.38	$18K
Grant/Award	Common Stock	1,629	$10.90	$18K

Holdings After Transaction: Common Stock — 23,469 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
2. F2. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

Key Figures

June 2026 RSU grant: 1,434 shares at $12.38 March 2026 RSU grant: 1,629 shares at $10.90 Post-transaction holdings: 23,469 shares +2 more

5 metrics

June 2026 RSU grant 1,434 shares at $12.38 Common Stock grant on June 1, 2026

March 2026 RSU grant 1,629 shares at $10.90 Common Stock grant on March 2, 2026

Post-transaction holdings 23,469 shares Direct holdings after June 1, 2026 grant

RSU vesting period 1 month RSUs vest one month from grant date

Transaction code A (grant/award acquisition) Both transactions reported as non-derivative grants

Key Terms

restricted stock units, RSUs, contingent right, administrative error, +1 more

5 terms

restricted stock units financial

"The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"The RSUs were received in lieu of cash retainers for board and committee compensation."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

contingent right financial

"RSUs, which represent a contingent right to receive one share of Common Stock for each RSU."

administrative error other

"Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely."

board and committee compensation financial

"The RSUs were received in lieu of cash retainers for board and committee compensation."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MiNK Therapeutics (INKT) disclose for Barbara Ryan?

MiNK Therapeutics disclosed that director Barbara Ryan received two stock grants as board compensation, not open-market trades. She was awarded 1,434 shares on June 1, 2026 and 1,629 shares on March 2, 2026, both in lieu of cash retainers for board and committee service.

Were the MiNK Therapeutics (INKT) transactions open-market stock purchases or sales?

The reported MiNK Therapeutics transactions were not open-market buys or sells. They were stock awards coded as “A” for grants, representing restricted stock units given instead of cash board and committee retainers, with no indication of discretionary market trading by the director.

How many MiNK Therapeutics (INKT) shares does Barbara Ryan hold after these grants?

After the June 1, 2026 grant, Barbara Ryan directly holds 23,469 MiNK Therapeutics common shares. This total reflects cumulative director compensation awards, including the 1,434-share grant in June 2026 and the 1,629-share grant in March 2026 reported in the same Form 4 filing.

What are the terms of the MiNK Therapeutics (INKT) restricted stock units granted?

The restricted stock units each represent a contingent right to receive one MiNK Therapeutics common share. According to the filing, these RSUs were issued instead of cash retainers and will vest one month from their grant date, after which the corresponding common shares are delivered to the director.

Why does the MiNK Therapeutics (INKT) Form 4 mention an administrative error?

The Form 4 notes that RSUs related to Q1 2026 board and committee compensation were not filed on time due to an administrative error. This comment explains the delay in reporting those earlier compensation-related units, rather than indicating any change to the underlying stock awards themselves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Barbara

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		1,629	A	$10.9(2)	22,035	D
Common Stock	06/01/2026		A		1,434	A	$12.38(1)	23,469	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

2. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

	By: /s/ Melissa Orilall, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)